Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CEA CAR-T cells + fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Sorrento Therapeutics
- Modality
- Small Molecules, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intra-arterial, Intravenous
01
Overview
NLIR + FU/FA is a combination therapy regimen developed by Sorrento Therapeutics for the treatment of CEA-expressing pancreatic adenocarcinoma with liver metastases. The regimen consists of regional hepatic infusions of autologous anti-CEA CAR-T cells (referred to as NLIR or CAR2) alternating with systemic chemotherapy comprising 5-fluorouracil (FU) and folinic acid (FA, also known as leucovorin). The CAR-T cells are engineered to target Carcinoembryonic Antigen (CEA), a protein frequently overexpressed in gastrointestinal cancers. The NLIR (Next-generation Liver-Intra-arterial Regional) delivery method utilizes the TriSalus Pressure-Enabled Drug Delivery (PEDD) device to administer the CAR-T cells directly into the hepatic artery, aiming to overcome the high interstitial fluid pressure of solid tumors and enhance the infiltration of the engineered T cells into liver metastases. The alternating systemic FU/FA chemotherapy is intended to provide synergistic anti-tumor activity and systemic disease control.
- Other names
- NLIR + FU/FAHITM-CEA CAR-T + 5-FU/LVanti-CEA CAR-T cells + 5-FU/LV
02
Targets
TS (Thymidylate synthase)CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)DNA
Beyond the preview
Go deeper on anti-CEA CAR-T cells + fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CEA CAR-T cells + fluorouracil + leucovorin.